AACR: Novartis aims to keep canakinumab’s early lung cancer hopes alive despite metastatic failurenews2022-04-12T15:24:58+00:00April 12th, 2022|Fierce Pharma|
Myovant, Pfizer’s expansion bid for Myfembree hits a snag at the FDAnews2022-04-12T13:38:37+00:00April 12th, 2022|Fierce Pharma|
Novartis’ global revamp to cost thousands of jobs for simpler structures: reportnews2022-04-12T13:25:21+00:00April 12th, 2022|Fierce Pharma|
Pfizer’s COVID pill Paxlovid gets boost in Britain thanks to spot in national trialnews2022-04-12T13:02:30+00:00April 12th, 2022|Fierce Pharma|
BioNTech sets sights on oral mRNA vaccines with deal to access Matinas delivery technologynews2022-04-12T11:57:42+00:00April 12th, 2022|Fierce Pharma|
Abzena nabs $65M to bolster manufacturing and research services on both sides of the pondnews2022-04-12T11:17:42+00:00April 12th, 2022|Fierce Pharma|
RLS bags $10M to trial dry powder inhaled CBD in anxietynews2022-04-12T10:37:28+00:00April 12th, 2022|Fierce Pharma|
Salvat heads to regulators with phase 3 data on ocular steroidnews2022-04-12T10:32:51+00:00April 12th, 2022|Fierce Pharma|
Hailing ‘paradigm shift,’ Clayton gets FDA oral suspension OK to challenge AbbVienews2022-04-12T10:27:58+00:00April 12th, 2022|Fierce Pharma|
Wherefore Tavneos? ChemoCentryx and the Brand Institute explain how the #FierceMadness winner got its namenews2022-04-12T08:12:25+00:00April 12th, 2022|Fierce Pharma|
